Dongsheng Tang

Mar 22, 2024 | onlinelibrary.wiley.com | Yan Xu |Dongsheng Tang |Leijiao Li |Xuan Li

Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description adfm202315385-sup-0001-SuppMat.pdf1.6 MB Supporting Information References 1, , , , , , , , , , , , ACS Nano. 2019, 13, 2427. 2a) , , , , , , , , , , Adv. Mater. 2019, 31, 1902530; b) , , , , , Biosaf. Health. 2022, 4, 87. 3a) , , , , , Nano-Micro Lett. 2020, 12, 2311; b) , , , , , Nanoscale. 2023, 15, 19638; c) , , , , , , , J. Am. Chem. Soc. 2022, 144, 11326.

Mar 24, 2023 | onlinelibrary.wiley.com | Tumpa Sadhukhan |Samya Banerjee |Dongsheng Tang |Ganghao Liang

Introduction The PtII complexes cisplatin, oxaliplatin, and carboplatin are some of the most frequently applied anticancer agents.1 Recent statistical findings have suggested that these compounds are used in more than 50 % of all chemotherapeutic treatments worldwide.2 Despite their undoubtful clinical success, the application of these metal complexes is hindered by their severe side effects (i.e., nausea, vomiting, kidney damage, and bone marrow suppression), poor tumor accumulation, and...